Home›Stocks›IDXX

IDXX — structural market context

IDEXX Laboratories, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 3. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 2 close to the Nov 3 close: +0.06%.

Volume

1.88× its 20-session average on Nov 3.

Includes pre- and post-market trading.

Short interest

Short interest 1.9M shares (settlement Oct 15) vs 1.9M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Oct 1–Oct 14, published Nov 3): 1 day with fails, largest 3 shares on Oct 6.

Previous file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 31 shares on Sep 17.

No new file loaded in this window.

Analyst rating actions

2 rating actions recorded.

UBS — Rating maintained — Nov 3

UBS — Price target change — Nov 3

Insider filings (Form 4)

1 Form 4 filing recorded, with 1 transaction: 0 purchase transactions (code P, $0), 0 sale transactions (code S, $0).

Filed Nov 3. Form 4 data arrives about a day after filing.

Events · early sample

None recorded in this window.

IDXX events and their magnitude

Latest SEC filing in the event study

Form 4 · other · filed 2026-11-03 · View on sec.gov ↗

…

How the Event Study works →

IDXX short interest & days to cover

SHARES SHORT

1.9M

% OF FLOAT

2.5%

DAYS TO COVER

3.6

CHANGE VS PRIOR

-0.6%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (20d ago)

How short interest and days to cover are measured →

IDXX fails-to-deliver (FTD)

Settlement date	Failed shares	Price
2026-10-06 · 29d	3	$527.07
2026-09-17 · 48d	31	$513.62
2026-09-11 · 54d	2	$506.53

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

IDXX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 1 sale

Insider	Type	Shares	Value	Filed
Kingsley Lawrence D · director	Sale (S)	2K	$1.2M	2026-09-09

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

IDXX analyst ratings

Firm	Action	Rating	Published
UBS	hold	Neutral	2026-11-03
UBS	price_target	—	2026-11-03
UBS	price_target	—	2026-10-27
Goldman Sachs	initialise	Buy	2026-10-16
Goldman Sachs	price_target	—	2026-10-16

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is IDXX's short interest?

As of the FINRA settlement date 2026-10-15, IDXX had 1.9M shares sold short — 2.5% of its float, with 3.6 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.

Are insiders buying IDXX?

In the last 12 months of SEC Form 4 filings, IDXX recorded 0 insider purchases and 1 sale reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.

What do analysts say about IDXX?

The most recent action: UBS hold to Neutral on 2026-11-03. Rating actions are shown as published by the firms; they are not graded here.

Is this page telling me to buy or sell IDXX?

No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.

All covered stocks Short Interest & FTD tracker Insider Buying tracker The platform

Other companies in the same SEC industry: In Vitro & In Vivo Diagnostic Substances

ACHV · Achieve Life Sciences, Inc. Co TKNO · Alpha Teknova, Inc.MYGN · Myriad Genetics, Inc.BMRA · Biomerica, Inc.CLDX · Celldex Therapeutics, Inc.LNTH · Lantheus Holdings, Inc.

Industry: SIC code 2835 as recorded on SEC EDGAR.

All tickers starting with I →

IDXX: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.